Protheragen, a specialized Contract Research Organization (CRO) dedicated to preclinical obesity research, today announced the launch of its Obesity Microbiota Research Service, an end-to-end research solution designed to examine the relationship between gut microbiota and obesity. The service encompasses animal model development, sample collection, 16S rRNA gene sequencing and/or shotgun metagenomic sequencing, and advanced bioinformatics and analytics. Leveraging research in obesity, microbiomics, and systems biology, the service focuses on identifying and prioritizing microbial targets that can aid in the development of next-generation anti-obesity therapeutics for biotechnology and pharmaceutical companies.
Research indicates that imbalances in gut microbial populations can influence the development of metabolic disorders and obesity, and ongoing work aims to elucidate the mechanisms by which these microbial populations contribute to obesity and to develop therapeutic strategies that modulate them. Protheragen’s Obesity Research Platform provides biotechnology and pharmaceutical companies with an integrated system to perform preclinical research on obesity and related disorders, facilitate the identification of therapeutic targets, and support the development of personalized microbiome-modulating strategies.
The Obesity Microbiota Research Service standardizes and streamlines its processes to provide clients with reproducible data. Once an appropriate animal model (e.g., mice or rats) is selected, the service can induce obesity using various means, including dietary manipulations, environmental modifications, and genetic manipulations. After sample collection (e.g., blood, feces, and intestinal tissues), the service provides specialized processing to protect the microbial contents and increase the precision of analysis. The service uses various techniques—including 16S rRNA gene sequencing, metagenomics, and metabolomics—to characterize microbial components and their metabolites, and to elucidate their effects on host physiology. Various bioinformatics and statistical tools are used to analyze the data and draw conclusions regarding the functional capabilities of the microbial components and their roles in obesity. This service provides clients with the ability to understand functionally important microbial components and groups, identify dysbiotic microbiota associated with obesity, and support the development of microbiota-based therapies for obesity.
Beyond microbiota-focused studies, the Obesity Microbiota Research Service is part of the broader Obesity Research Platform, which supports the entire spectrum of anti-obesity therapeutic development—including small-molecule drugs that modulate the gut microbiota, gene and cell therapies, antibody therapies, tissue engineering, and other transformative approaches. Rigorous preclinical validation is conducted to provide scientific justification for advancing a therapeutic candidate to clinical trials. Each candidate undergoes pharmacodynamic and pharmacokinetic studies, toxicological evaluation, and safety assessment, with bioanalytical support provided throughout.
About Protheragen
Protheragen is a specialized Contract Research Organization (CRO) dedicated to advancing preclinical research in obesity. Driven by a passion for scientific innovation and a commitment to client success, the company has established a reputation for delivering high-quality data, actionable insights, and tailored solutions that drive breakthroughs in obesity therapeutics. Its integrated Obesity Research Platform seamlessly combines expertise across metabolism, inflammation, and cardiovascular biology, enabling a holistic approach to obesity research and therapy development. The company maintains quality control standards throughout its preclinical services to support the integrity and regulatory acceptance of generated data. For more information about the Obesity Microbiota Research Service, please contact Protheragen.
